Latest News and Press Releases
Want to stay updated on the latest news?
-
SAN RAFAEL, Calif., Sept. 15, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the European Medicines Agency (EMA) validated the Marketing Authorization...
-
SAN RAFAEL, Calif., Sept. 08, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that two oral and 16 poster presentations related to the company’s products and...
-
Additional Data Submitted to BLA following FDA Request, PDUFA Action Date Extended to April 27, 2017 Additional 8 Months of Treatment (81-Week Data) Show Maintenance of Efficacy, Consistent with...
-
EU and U.S. Marketing Application Submissions Planned for Mid-Year 2016 Company Seeking Priority Review in the U.S. SAN RAFAEL, Calif., May 03, 2016 (GLOBE NEWSWIRE) -- BioMarin...
-
80% Reduction in Clinical Disease Progression in One Year Compared to Natural History (p <0.0001) Company Plans to Submit Marketing Applications Starting Mid-Year 2016 SAN RAFAEL, Calif., March...